| Authors: |
Kunnen SJ; Leiden University, Leiden Academic Centre for Drug Research (LACDR), Division of Cell Systems and Drug Safety, Leiden, the Netherlands., Callegaro G; Leiden University, Leiden Academic Centre for Drug Research (LACDR), Division of Cell Systems and Drug Safety, Leiden, the Netherlands., Sutherland JJ; Vesalius Therapeutics, Cambridge, MA, USA., Trairatphisan P; Sanofi, R&D Preclinical Safety, Industriepark Hoechst, Frankfurt am Main, Germany.; Heidelberg University, Faculty of Medicine, Institute for Computational Biomedicine, Heidelberg, Germany., van Kessel HW; Leiden University, Leiden Academic Centre for Drug Research (LACDR), Division of Cell Systems and Drug Safety, Leiden, the Netherlands., Wijaya LS; Leiden University, Leiden Academic Centre for Drug Research (LACDR), Division of Cell Systems and Drug Safety, Leiden, the Netherlands., Chung G; Newcells Biotech, Newcastle, UK., Pye K; Newcells Biotech, Newcastle, UK., Goldstein KM; Lilly Research Laboratories, Eli Lilly and Company Ltd, Indianapolis, IN, USA., Teague CR; GSK, Clinical Pharmacology and Experimental Medicine, Stevenage, UK., Fisher CP; GSK, Target and Systems Safety, Nonclinical Safety, Stevenage, UK., Saez-Rodriguez J; Heidelberg University, Faculty of Medicine, Institute for Computational Biomedicine, Heidelberg, Germany., Brown C; Newcells Biotech, Newcastle, UK., Elmore SA; ElmorePathology, LLC, Chapel Hill, NC, USA., Heinz-Taheny KM; Lilly Research Laboratories, Eli Lilly and Company Ltd, Indianapolis, IN, USA., Stevens JL; Leiden University, Leiden Academic Centre for Drug Research (LACDR), Division of Cell Systems and Drug Safety, Leiden, the Netherlands., van de Water B; Leiden University, Leiden Academic Centre for Drug Research (LACDR), Division of Cell Systems and Drug Safety, Leiden, the Netherlands. |
